John Hey

Company: Alzheon

Job title: Chief Scientific Officer

Seminars:

Panel Discussion: How has the Recent Approval of Disease Modifying Drugs Impacted the Treatment Landscape for Alzheimer’s Disease? 9:30 am

Exploring the potential impact on novel target discovery and development strategies Illuminating the impact on clinical development plans in demonstrating meaningful effect on patients Reviewing how trial design might be impacted with Leqembi as a comparator or combination partner in future studiesRead more

day: Conference Day Two

2-Year Effects of Alz-801/Valiltramiprosate on Plasma Fluid Biomarkers, Volumetric MRI Biomarkers & Cognition Support Disease Modification In APOE4 Carriers With Early Alzheimer’s Disease 11:00 am

Evaluating ALZ-801 in EAD (early Alzheimer’s Disease) patients that are APoE4 carriers as measured by fluid biomarkers e.g. p-tau 181, imaging and clinical outcomes Highlighting a disease modifying effect and dynamic biomarker analysis over a 2-year period Evaluating potential disease modifying effects of ALZ-801 as an oral anti-oligomer agent in phase 3 development that demonstrating…Read more

day: Clinical & Commercial Track AM